ArticleDiabetes, obesity, and cardiometabolic CARE
Physical Activity Patterns in Adults Taking Glucagon-Like Peptide 1 Receptor Agonists: An
Article in Diabetes, obesity, and cardiometabolic CARE. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTreatment with a glucagon-like peptide 1 receptor agonist (GLP-1RA) is an effective pharmacotherapy for obesity and diabetes care, but physical activity patterns among adults taking this class of medication have not been well described. Thus, the objective of this study was to characterize physical activity patterns in U.S. adults taking a GLP-1RA and identify sociodemographic and clinical factors associated with low activity levels. RESEARCH DESIGN AND
methodsWe conducted a cross-sectional study using data from the National Institutes of Health
resultsAmong 298 participants (mean ± SD age 52.6 ± 12.6 years), daily total physical activity time was 204 ± 76 min, including 24 ± 21 min of moderate-to-vigorous activity. More than half of participants (57.7%) did not meet the recommended ≥150 min/week of moderate-to-vigorous activity. Mean step count/day ± SD was 5,944 ± 2,699 steps and sedentary time/day was 947 ± 189 min. Injectable semaglutide was associated with a greater amount of physical activity, whereas older age, female sex, lower income, and diabetes were associated with less activity.
conclusionsThe majority of adults taking a GLP-1RA did not meet recommended levels of physical activity. Findings highlight the need for targeted interventions to promote physical activity among adults taking a GLP-1RA and suggest a beneficial relationship between semaglutide and a more active lifestyle, which will need to be explored in future studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.